# TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

> **NCT03192462** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 37 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** multiTAA specific T cells

## Key facts

- **NCT ID:** NCT03192462
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-18
- **Primary completion:** 2020-06-15
- **Final completion:** 2025-07-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192462, "TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03192462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*